ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
0,00%
Bitcoin
63 778,25
-0,18%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Eloxx Pharmaceuticals Inc (ELOX)

  7. Eloxx Pharmaceuticals Inc (ELOX) Actualités

ELOX Eloxx Pharmaceuticals Inc

3,82
0,00 (0,00%)
03 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Eloxx Pharmaceuticals Inc ELOX NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 3,82 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
3,82 3,82
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
16/4/202413:30GLOBEEloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program..
01/4/202422:02EDGAR2Form NT 10-K - Notification of inability to timely file Form..
29/3/202421:11EDGAR2Form 8-K - Current report
21/3/202419:20EDGAR2Form 25-NSE - Notification filed by national security..
14/3/202421:30EDGAR2Form 8-K - Current report
13/3/202416:42GLOBEAlmirall and Eloxx Pharmaceuticals Enter into Exclusive..
26/1/202422:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/1/202422:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/1/202422:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/1/202422:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/1/202403:44EDGAR2Form S-3 - Registration statement under Securities Act of..
24/1/202423:11EDGAR2Form S-8 - Securities to be offered to employees in employee..
09/1/202423:10EDGAR2Form 8-K - Current report
28/12/202322:11EDGAR2Form 8-K - Current report
13/11/202322:15GLOBEEloxx Pharmaceuticals Reports Third Quarter 2023 Financial..
16/10/202323:26EDGAR2Form 8-K - Current report
09/10/202314:00GLOBEEloxx Pharmaceuticals Reports Additional Confirmation that..
20/9/202322:05EDGAR2Form 8-K - Current report
20/9/202319:26EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
19/9/202314:00GLOBEEloxx Pharmaceuticals Announces $2 Million Registered Direct..
18/9/202314:05EDGAR2Form 8-K - Current report
18/9/202313:00GLOBEEloxx Pharmaceuticals Reports Independent Confirmation of..
15/9/202323:15EDGAR2Form 8-K - Current report
07/9/202316:14EDGAR2Form 8-K - Current report
07/9/202315:00GLOBEEloxx Pharmaceuticals Provides Program Updates on ELX-02 and..
29/8/202322:32EDGAR2Form 8-K - Current report
21/8/202322:50EDGAR2Form 8-K - Current report
14/8/202317:56EDGAR2Form 8-K - Current report
14/8/202314:30GLOBEEloxx Pharmaceuticals Reports Second Quarter 2023 Financial..
14/8/202314:00GLOBEEloxx Pharmaceuticals Reports Drug Response in All Patients..
11/8/202322:11EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
11/8/202322:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/8/202322:01EDGAR2Form 8-K - Current report
03/8/202315:26GLOBEEloxx Pharmaceuticals Granted Extension by Nasdaq to Regain..
13/7/202314:43EDGAR2Form 8-K - Current report
10/7/202315:00GLOBEEloxx Pharmaceuticals Announces Publication Demonstrating..
28/6/202315:00GLOBEEloxx Pharmaceuticals Key Opinion Leader Event Highlights..
21/6/202319:30GLOBEEloxx Pharmaceuticals to Host Investor and Analyst Call on..
21/6/202315:00GLOBEEloxx Pharmaceuticals Highlights Recent Alport Syndrome..
14/6/202322:53GLOBEEloxx Pharmaceuticals Announces Final Data Assessment from..
06/6/202314:30GLOBEEloxx Pharmaceuticals Granted Extension by Nasdaq to Regain..
01/6/202315:10GLOBEAtossa Appoints Life Sciences Financial and Operations..
24/5/202314:00GLOBEEloxx Pharmaceuticals Intends to Advance ELX-02 into Pivotal..
15/5/202322:30GLOBEEloxx Pharmaceuticals Reports First Quarter 2023 Financial..

Dernières Valeurs Consultées

NASDAQ
ELOX
Eloxx Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés